A UK cohort study used drug concentration samples from rheumatoid arthritis patients starting the adalimumab biosimilar Amgevita and the etanercept biosimilar Benepali to simulate drug levels under standard and alternate dosing schedules, suggesting that personalized dosing could reduce costs while potentially increasing efficacy.
Using drug concentration samples from patients with rheumatoid arthritis (RA) starting the adalimumab biosimilar Amgevita and the etanercept biosimilar Benepali, a UK cohort study simulated drug concentration during standard and alternate dosing schedules. According to the authors, simulating different dosing intervals “could form the basis for future personalised dosing studies, potentially saving costs whilst increasing efficacy.”
Image credit: DachAI - stock.adobe.com
The effectiveness of tumor necrosis factor (TNF)-α inhibitors is affected by circulating drug levels, and there is between-subject variability in circulating drug levels, the authors said. The study included 10, real-world patients with RA starting the adalimumab biosimilar Amgevita and 6 starting the etanercept biosimilar Benepali. The authors noted that the number of participants was “below those planned” due to the COVID-19 pandemic. Drug concentration samples were collected over a 12-week period for each patient, a total of 58 samples of patients receiving adalimumab and 40 from patients receiving etanercept. The drug concentration data was used to estimate pharmacokinetic parameters, which in turn were used to model population pharmacokinetics.
The investigators wrote that plots of predicted vs observed measurements confirmed that the estimated parameters “described the data adequately.” The estimated parameters were used to simulate and compare typical and altered dosing intervals of each drug. The authors added that simulated profiles of typical dosing were overlaid with observed plasma concentration data, which demonstrated that the simulated results “agreed well with the data.” The models produced simulated typical individual profiles, plus medians and fifth and 95th percentiles for each drug and dosing interval combination.
Compared to the usual dosing interval of the adalimumab biosimilar, 40 mg every 14 days, 40 mg every 7 days also resulted in steady-state adalimumab concentrations within the therapeutic window, and differences in time to steady-state concentration between these two dosing intervals were “negligible.” However, a reduction to 40 mg every 21 days did not result in steady-state concentrations within the therapeutic window.
Compared to the typical dosing interval of the etanercept biosimilar 50 mg every 7 days, the simulated dosing intervals of 50 mg every 5 days and 50 mg every 10 days “achieved steady-state drug concentrations well above the therapeutic window,” the authors wrote. Differences between dosing intervals in time to steady-state concentration were “negligible,” but “marginally quicker with an interval of every 10 days on visual inspection.”
The authors added that patients on the adalimumab biosimilar had a higher median body weight than those on the etanercept biosimilars, which could have affected the simulation results, as previous studies have suggested the response to anti-TNF treatment is reduced at higher body mass index. They also acknowledged a lack of testing for antidrug antibodies as a limitation of their study, since anti-adalimumab antibodies “are associated with decreased drug concentrations and reduced rates of treatment response.” Despite these limitations and the small sample size, they said their study “adds valuable information and data in a space where both are very limited,” and findings from simulations of altered dosing intervals could lead to personalized dosing for adalimumab and etanercept.
Reference
Ling SF, Ogungbenro K, Darwich AS, et al. Population pharmacokinetic analysis and simulation of alternative dosing regimens for biosimilars to adalimumab and etanercept in patients with rheumatoid arthritis. Pharmaceutics. 2024;16(6):702. doi:10.3390/pharmaceutics16060702.
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.